

## Lupus érythémateux systémique: quelle prise en charge raisonnable en 2013?

## Systemischer Lupus erythematosus: Wie im Jahr 2013 sinnvoll behandeln?

### Literatur / Références

1. Tsokos GC. Systemic lupus erythematosus. *The New England journal of medicine*. 2011 Dec 1;365(22):2110–21. PubMed PMID: 22129255.
2. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. *Seminars in arthritis and rheumatism*. 2010 Feb;39(4):257–68. PubMed PMID: 19136143. Pubmed Central PMCID: 2813992.
3. Hahn BH. Belimumab for systemic lupus erythematosus. *The New England journal of medicine*. 2013 Apr 18;368(16):1528–35. PubMed PMID: 23594005.
4. Haq I, Isenberg DA. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice? *Best practice & research Clinical rheumatology*. 2002 Apr;16(2):181–94. PubMed PMID: 12041948.
5. Gladman DD, Ibanez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. *The Journal of rheumatology*. 2013 May;40(5):630–3. PubMed PMID: 23457385.
6. Manzi S. Lupus update: perspective and clinical pearls. *Cleveland Clinic journal of medicine*. 2009 Feb;76(2):137–42. PubMed PMID: 19188480.
7. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. *Arthritis care & research*. 2012 Jun;64(6):797–808. PubMed PMID: 22556106. Pubmed Central PMCID: 3437757.
8. Ball EM, Bell AL. Lupus arthritis--do we have a clinically useful classification? *Rheumatology*. 2012 May;51(5):771–9. PubMed PMID: 22179731.
9. Appel GB. New and future therapies for lupus nephritis. *Cleveland Clinic journal of medicine*. 2012 Feb;79(2):134–40. PubMed PMID: 22301564.
10. Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. *Rheumatology*. 2011 Aug;50(8):1401–8. PubMed PMID: 21398661.
11. Fernandez-Nebro A, de la Fuente JL, Carreno L, Izquierdo MG, Tomero E, Rua-Figueroa I, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. *Lupus*. 2012 Sep;21(10):1063–76. PubMed PMID: 22786985.
12. Pego-Reigosa JM, Cobo-Ibanez T, Calvo-Alen J, Loza-Santamaria E, Rahman A, Munoz-Fernandez S, et al. Efficacy and safety of non-biologic immunosuppressants in the treatment of non-renal systemic lupus erythematosus: A systematic review. *Arthritis care & research*. 2013 Apr 22. PubMed PMID: 23609987.
13. Winzer M, Aringer M. Use of methotrexate in patients with systemic lupus erythematosus and primary Sjogren's syndrome. *Clinical and experimental rheumatology*. 2010 Sep-Oct;28(5 Suppl 61):S156–9. PubMed PMID: 21044451.
14. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Annals of the rheumatic diseases*. 2010 Jan;69(1):20–8. PubMed PMID: 19103632.
15. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF, American Academy of O. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. *Ophthalmology*. 2011 Feb;118(2):415–22. PubMed PMID: 21292109.
16. Merrill JT. Treatment of systemic lupus erythematosus: a 2012 update. *Bulletin of the NYU hospital for joint diseases*. 2012;70(3):172–6. PubMed PMID: 23259624.
17. Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. *Rheumatology*. 2012 Jul;51(7):1145–53. PubMed PMID: 22271756.
18. Zouali M, Uy EA. Belimumab Therapy in Systemic Lupus Erythematosus. *BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy*. 2013 Apr 9. PubMed PMID: 23568179.
19. Lutalo PM, D'Cruz DP. Belimumab for the management of systemic lupus erythematosus. *Expert opinion on biological therapy*. 2012 Jul;12(7):957–63. PubMed PMID: 22646798.

20. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011 Feb 26;377(9767):721–31. PubMed PMID: 21296403.
21. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis and rheumatism*. 2011 Dec;63(12):3918–30. PubMed PMID: 22127708.
22. Wofsy D. Recent progress in conventional and biologic therapy for systemic lupus erythematosus. *Annals of the rheumatic diseases*. 2013 Apr;72 Suppl 2:ii66–ii8. PubMed PMID: 23253930.
23. Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, Ocana-Medina C, Sanchez-Roman J. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. *Rheumatology*. 2012 Oct;51(10):1918–9. PubMed PMID: 22513150.
24. Paz Z, Tsokos GC. New therapeutics in systemic lupus erythematosus. *Current opinion in rheumatology*. 2013 May;25(3):297–303. PubMed PMID: 23492737.
25. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis and rheumatism*. 1982 Nov;25(11):1271–7. PubMed PMID: 7138600.